Novel des-γ-carboxy prothrombin in serum for the diagnosis of hepatocellular carcinoma

Journal of Gastroenterology and Hepatology (Australia)

Volumn 28, Issue 8, 2013, Pages 1348-1355

  Tanaka, Takahiro ^a   Taniguchi, Tatsuya ^a   Sannomiya, Katsutaka ^a   Takenaka, Hidetaka ^a   Tomonari, Tetsu ^a   Okamoto, Koichi ^a   Kitamura, Shinji ^a   Okahisa, Toshiya ^a   Tamaki, Katsuyoshi ^a   Mikasa, Hiroaki ^b   Suzuki, Sadao ^c   Takayama, Tetsuji ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b UNIVERSITY OF TOKUSHIMA   (Japan)

^c NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

Author keywords

Des carboxyl prothrombin; Hepatocellular carcinoma; Obstructive jaundice; Warfarin

Indexed keywords

DECARBOXYPROTHROMBIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY MU 3; MONOCLONAL ANTIBODY P11; MONOCLONAL ANTIBODY P16; PROTEIN ANTIBODY; TUMOR MARKER; UNCLASSIFIED DRUG; WARFARIN;

AFFINITY CHROMATOGRAPHY; ANTICOAGULANT THERAPY; ARTICLE; CANCER DIAGNOSIS; CANCER PATIENT; CANCER TISSUE; CHEMILUMINESCENCE IMMUNOASSAY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; ELECTROCHEMILUMINESCENCE IMMUNOASSAY; FEMALE; HEART DISEASE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; OBSTRUCTIVE JAUNDICE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN ISOLATION; RECEIVER OPERATING CHARACTERISTIC; WESTERN BLOTTING;

EID: 84880670745     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12166     Document Type: Article

References (27)

1. Liebman HA, Furie BC, Tong MJ etal. Des-gamma-carboxy (abnormal) prothrombinas a serum marker of primary hepatocellular carcinoma. N. Engl. J. Med. 1984; 310: 1427-1431.
2. Marrero JA, Su GL, Wei W etal. Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in American patients. Hepatology 2003; 37: 1114-1121.
3. Yamamoto K, Imamura H, Matsuyama Y etal. AFP, AFP-L3, DCP, and GP73 as markers for monitoring treatment response and recurrence and as surrogate markers of clinicopathological variables of HCC. J. Gastroenterol. 2010; 45: 1272-1282.
4. Lok AS, Sterling RK, Everhart JE etal. Des-gamma-carboxyprothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology 2010; 138: 493-502.
5. Soulier JP, Gozin D, Lefrere JJ. A new method to assay des-gamma-carboxyprothrombin. Results obtained in 75 cases of hepatocellular carcinoma. Gastroenterology 1986; 91: 1258-1262.
6. Nakamura S, Nouso K, Sakaguchi K etal. Sensitivity and specificity of des-gamma-carboxyprothrombin for diagnosis of patients with hepatocellular carcinomas varies according to tumor size. Am. J. Gastroenterol. 2006; 101: 2038-2043.
7. Sterling RK, Jeffers L, Gordon F etal. Utility of Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein and des-gamma-carboxyprothrombin, alone or in combination, as biomarkers for hepatocellular carcinoma. Clin. Gastroenterol. Hepatol. 2009; 7: 104-113.
8. Baek YH, Lee JH, Jang JS etal. Diagnostic role and correlation with staging systems of PIVKA-II compared with AFP. Hepatogastroenterology 2009; 56: 763-767.
9. Imamura H, Matsuyama Y, Miyagawa Y etal. Prognostic significance of anatomical resection and des-gamma-carboxyprothrombin in patients with hepatocellular carcinoma. Br. J. Surg. 1999; 86: 1032-1038.
10. Kobayashi M, Ikeda K, Kawamura Y etal. High serum des-gamma-carboxyprothrombin level predicts poor prognosis after radiofrequency ablation of hepatocellular carcinoma. Cancer 2009; 115: 571-580.
11. Suzuki M, Shiraha H, Fujikawa T etal. Des-gamma-carboxyprothrombin is a potential autologous growth factor for hepatocellular carcinoma. J. Biol. Chem. 2005; 280: 6409-6415.
12. Fujikawa T, Shiraha H, Ueda N etal. Des-gamma-carboxyl prothrombin-promoted vascular endothelial cell proliferation and migration. J. Biol. Chem. 2007; 282: 8741-8748.
13. Furie B, Furie BC. Molecular basis of vitamin K-dependent gamma-carboxylation. Blood 1990; 75: 1753-1762.
14. Suttie JW. Vitamin K-dependent carboxylase. Annu. Rev. Biochem. 1985; 54: 459-477.
15. Uehara S, Gotoh K, Handa H, Honjo K, Hirayama A. Process of carboxylation of glutamic acid residues in the gla domain of human des-gamma-carboxyprothrombin. Clin. Chim. Acta 1999; 289: 33-44.
16. Lee W, Chung HJ, Kim S, Jang S etal. PIVKA-II is a candidate marker for monitoring the effects of the oral anticoagulant warfarin. Clin. Biochem. 2010; 43: 1177-1179.
17. Nakao A, Suzuki Y, Isshiki K etal. Clinical evaluation of plasma abnormal prothrombin (des-gamma-carboxyprothrombin) in hepatobiliary malignancies and other diseases. Am. J. Gastroenterol. 1991; 86: 62-66.
18. Okuda H, Nakanishi T, Takatsu K etal. Measurement of serum levels of des-gamma-carboxyprothrombin in patients with hepatocellular carcinoma by a revised enzyme immunoassay kit with increased sensitivity. Cancer 1999; 85: 812-818.
19. Naraki T, Kohno N, Saito H etal. γ-Carboxyglutamic acid content of hepatocellular carcinoma-associated des-gamma-carboxy prothrombin. Biochim. Biophys. Acta 2002; 1586: 287-298.
20. Uehara S, Gotoh K, Handa H, Tomita H, Senshuu M. Distribution of the heterogeneity of des-gamma-carboxyprothrombin in patients with hepatocellular carcinoma. J. Gastroenterol. Hepatol. 2005; 20: 1545-1552.
21. Toyoda H, Kumada T, Osaki Y etal. Novel method to measure serum levels of des-gamma-carboxyprothrombin for hepatocellular carcinoma in patients taking warfarin: a preliminary report. Cancer Sci. 2012; 103: 921-925.
22. Matsui O, Ueda K, Kobayashi S etal. Intra- and perinodular hemodynamics of hepatocellular carcinoma: CT observation during intra-arterial contrast injection. Abdom. Imaging 2002; 27: 147-156.
23. Araki T, Itai Y, Furui S, Tasaka A. Dynamic CT densitometry of hepatic tumors. AJR Am. J. Roentgenol. 1980; 135: 1037-1043.
24. Takeuchi H, Kimura T, Okamoto K etal. A mechanism for abnormal angiogenesis in human radiation proctitis: analysis of expression profile for angiogenic factors. J. Gastroenterol. 2012; 47: 56-64.
25. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988; 44: 837-845.
26. Ueshima K, Kudo M, Takita M etal. Des-γ-carboxyprothrombin may be a promising biomarker to determine the therapeutic efficacy of sorafenib for hepatocellular carcinoma. Dig Dis 2011; 29: 321-325.
27. Nakazawa T, Hidaka H, Shibuya A, Koizumi W. Rapid regression of advanced hepatocellular carcinoma associated with elevation of des-gamma-carboxyprothrombin after short-term treatment with sorafenib-a report of two cases. Case Rep Oncol 2010; 3: 298-303.